[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse AGPAT3

Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein Nucleus envelope.
Domain PF16076 Acyltransferase C-terminus
PF01553 Acyltransferase
Function

Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. Acts on LPA containing saturated or unsaturated fatty acids C16:0-C20:4 at the sn-1 position using C18:1, C20:4 or C18:2-CoA as the acyl donor. Also acts on lysophosphatidylcholine, lysophosphatidylinositol and lysophosphatidylserine using C18:1 or C20:4-CoA (PubMed:21173190). Has a preference for arachidonoyl-CoA as a donor. Has also a modest lysophosphatidylinositol acyltransferase (LPIAT) activity, converts lysophosphatidylinositol (LPI) into phosphatidylinositol (By similarity).

> Gene Ontology
 
Biological Process GO:0006638 neutral lipid metabolic process
GO:0006639 acylglycerol metabolic process
GO:0006641 triglyceride metabolic process
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006654 phosphatidic acid biosynthetic process
GO:0008654 phospholipid biosynthetic process
GO:0016024 CDP-diacylglycerol biosynthetic process
GO:0019432 triglyceride biosynthetic process
GO:0045017 glycerolipid biosynthetic process
GO:0046341 CDP-diacylglycerol metabolic process
GO:0046460 neutral lipid biosynthetic process
GO:0046463 acylglycerol biosynthetic process
GO:0046473 phosphatidic acid metabolic process
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
Molecular Function GO:0003841 1-acylglycerol-3-phosphate O-acyltransferase activity
GO:0008374 O-acyltransferase activity
GO:0016411 acylglycerol O-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0042171 lysophosphatidic acid acyltransferase activity
GO:0071617 lysophospholipid acyltransferase activity
Cellular Component GO:0005635 nuclear envelope
> KEGG and Reactome Pathway
 
KEGG hsa00561 Glycerolipid metabolism
hsa00564 Glycerophospholipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-6811436: COPI-independent Golgi-to-ER retrograde traffic
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-1483206: Glycerophospholipid biosynthesis
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-199991: Membrane Trafficking
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1483257: Phospholipid metabolism
R-HSA-1483166: Synthesis of PA
R-HSA-75109: Triglyceride Biosynthesis
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AGPAT3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AGPAT3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AGPAT3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6770.0181
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5270.768
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7830.573
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7070.144
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6060.763
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8410.753
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1830.649
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2310.896
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0790.969
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.450.781
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7270.755
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1260.0773
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AGPAT3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AGPAT3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AGPAT3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AGPAT3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AGPAT3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AGPAT3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AGPAT3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAGPAT3
Name1-acylglycerol-3-phosphate O-acyltransferase 3
Aliases LPAAT-gamma; LPAAT-GAMMA1; LPAAT3; 1-AGP acyltransferase 3; 1-AGPAT 3; lysophosphatidic acid acyltransferase ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AGPAT3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.